MA45613A - Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique - Google Patents

Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique

Info

Publication number
MA45613A
MA45613A MA045613A MA45613A MA45613A MA 45613 A MA45613 A MA 45613A MA 045613 A MA045613 A MA 045613A MA 45613 A MA45613 A MA 45613A MA 45613 A MA45613 A MA 45613A
Authority
MA
Morocco
Prior art keywords
carbamoylpyridon
polycyclic
compounds
pharmaceutical use
pharmaceutical
Prior art date
Application number
MA045613A
Other languages
English (en)
Inventor
Elizabeth M Bacon
Zhenhong R Cai
Jeromy J Cottell
Mingzhe Ji
Haolun Jin
Scott E Lazerwith
Philip Anthony Morganelli
Hyung-Jung Pyun
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA45613A publication Critical patent/MA45613A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045613A 2014-12-23 2015-12-21 Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique MA45613A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462096291P 2014-12-23 2014-12-23

Publications (1)

Publication Number Publication Date
MA45613A true MA45613A (fr) 2021-04-28

Family

ID=55168426

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045613A MA45613A (fr) 2014-12-23 2015-12-21 Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique

Country Status (24)

Country Link
US (4) US9522912B2 (fr)
EP (2) EP3388431A1 (fr)
JP (3) JP6393835B2 (fr)
KR (4) KR102020004B1 (fr)
CN (2) CN107108643B (fr)
AR (1) AR103251A1 (fr)
AU (3) AU2015369817B2 (fr)
BR (1) BR102015032109A2 (fr)
CA (1) CA2969244C (fr)
EA (1) EA201791019A1 (fr)
ES (1) ES2732482T3 (fr)
HK (1) HK1244000B (fr)
IL (1) IL252532A0 (fr)
MA (1) MA45613A (fr)
MX (1) MX2017007814A (fr)
NZ (1) NZ732391A (fr)
PL (1) PL3237416T3 (fr)
PT (1) PT3237416T (fr)
SG (1) SG11201704421QA (fr)
SI (1) SI3237416T1 (fr)
TR (1) TR201909152T4 (fr)
TW (2) TWI695003B (fr)
UY (1) UY36465A (fr)
WO (1) WO2016106237A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016161382A1 (fr) * 2015-04-02 2016-10-06 Gilead Sciences, Inc. Composés carbamoylpyridones polycycliques et leur utilisation pharmaceutique
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
SG11202004009TA (en) * 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
CA3080971A1 (fr) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulateurs de la voie de reponse integree au stress
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
WO2019113419A1 (fr) * 2017-12-08 2019-06-13 The Rockefeller University Ligands du récepteur opioïde kappa pyrano [3,4-b] pyrazine pour le traitement de l'accoutumance, du prurit, de la douleur et de l'inflammation
RS65891B1 (sr) * 2018-05-31 2024-09-30 Shionogi & Co Policiklični karbamoilpiridonski derivati za lečenje hiv-a
PE20201414A1 (es) 2018-05-31 2020-12-07 Shionogi & Co Derivado policiclico de piridona
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
WO2021093846A1 (fr) * 2019-11-13 2021-05-20 上海拓界生物医药科技有限公司 Nouveaux composés hétérocycliques tétracycliques et leur utilisation pharmaceutique
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
WO2021107065A1 (fr) * 2019-11-28 2021-06-03 塩野義製薬株式会社 Dérivé de pyridopyrazine polycyclique
BR112022015771A2 (pt) 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
US20230106880A1 (en) * 2020-03-06 2023-04-06 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20230242587A1 (en) * 2020-04-17 2023-08-03 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Thyclotides
JP7695339B2 (ja) * 2020-07-27 2025-06-18 メルク・シャープ・アンド・ドーム・エルエルシー インフルエンザを治療又は予防するための多環式キャップ依存性エンドヌクレアーゼ阻害薬
TW202222798A (zh) 2020-09-30 2022-06-16 美商基利科學股份有限公司 橋接三環胺甲醯基吡啶酮化合物及其用途
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN114736173B (zh) * 2022-05-24 2024-06-11 无锡捷化医药科技有限公司 一种3-（二氟甲基）氧杂环丁烷-3-胺盐酸盐的制备方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
ID29027A (id) 1998-12-25 2001-07-26 Shionogi & Co Turunan-turunan heteroaromatik yang mempunyai aktivitas penghambatan terhadap integrase hiv
AU2001262732A1 (en) 2000-06-14 2001-12-24 Shionogi And Co., Ltd. Inhibitor for enzyme having two divalent metal ions as active centers
JP4338192B2 (ja) 2001-08-10 2009-10-07 塩野義製薬株式会社 抗ウイルス剤
NZ532018A (en) 2001-10-03 2004-12-24 Ucb S Pyrrolidinone derivatives
HU230248B1 (hu) 2001-10-26 2015-11-30 Msd Italia S.R.L. N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok
AU2003248872A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
EP1549315A4 (fr) 2002-09-11 2007-05-23 Merck & Co Inc Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
US7176220B2 (en) 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
WO2004049675A2 (fr) * 2002-11-26 2004-06-10 Ambient Corporation Agencement d'un coupleur inductif pour courants porteurs en lignes
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
CA2523083C (fr) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Analogues de phosphonate antiviraux
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
AU2005211349A1 (en) 2004-01-30 2005-08-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors
CN101014574A (zh) 2004-03-09 2007-08-08 默克公司 Hiv整合酶抑制剂
JP4824673B2 (ja) 2004-05-07 2011-11-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害剤
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
EP1758581A1 (fr) 2004-05-21 2007-03-07 Japan Tobacco, Inc. Associations comprenant un derivee de 4-isoquinolone et des agents anti-vih
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
EP1790638B1 (fr) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Dérivé de carbamoylpyridone ayant une activité d'inhibition de la vih intégrase
WO2006066414A1 (fr) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones et procedes d’inhibition de l’integrase du vih
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
DK1874117T3 (da) 2005-04-28 2013-09-23 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
US20060249072A1 (en) * 2005-05-05 2006-11-09 Csillag Frank J Method of synthesizing a fluoride growth material for improved outgassing
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
JP2009502964A (ja) 2005-07-27 2009-01-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを阻害するための抗ウイルス性ホスホン酸結合体
JP5131689B2 (ja) 2005-10-27 2013-01-30 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
AP2702A (en) 2005-12-30 2013-07-23 Gilead Sciences Inc Methods for improving the pharmacokinetics of HIV integrase inhibitors
US20090018162A1 (en) 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
JP4669040B2 (ja) 2006-03-06 2011-04-13 日本たばこ産業株式会社 ４−オキソキノリン化合物の製造方法
WO2007102499A1 (fr) 2006-03-06 2007-09-13 Japan Tobacco Inc. Procede de production d'un compose 4-oxoquinoline
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2008010953A2 (fr) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Dicétoacides de pyridinone : inhibiteurs de la réplication du vih dans une thérapie combinée
AU2007296555B2 (en) 2006-09-12 2012-07-12 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US20100216834A1 (en) 2006-10-18 2010-08-26 Isaacs Richard C A Hiv integrase inhibitors
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
NZ582086A (en) 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
CN101743004A (zh) 2007-06-29 2010-06-16 吉里德科学公司 治疗用组合物及其用途
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2010011813A1 (fr) 2008-07-23 2010-01-28 Alkermes, Inc. Complexe de trospium et ses compostions pharmaceutiques
WO2010011815A1 (fr) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
SI2320908T1 (sl) 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
WO2010011819A1 (fr) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
WO2010011818A1 (fr) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
PT2660239T (pt) * 2008-07-25 2017-02-24 Shionogi & Co Compostos químicos como intermediários sintéticos
WO2010011816A1 (fr) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
MX351942B (es) 2008-12-11 2017-11-03 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
ES2550101T3 (es) * 2008-12-17 2015-11-04 Merck Patent Gmbh Inhibidores de proteína quinasa de benzonaftiridinona tricíclica modificada con anillo C y su uso
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
US10065950B2 (en) 2010-02-26 2018-09-04 Japan Tobacco Inc. Substituted thiazoles as HIV integrase inhibitors
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
PT3456721T (pt) 2010-08-05 2021-05-04 Shionogi & Co Método de produção de compostos possuindo atividade inibitória de integrase de vih
US8987441B2 (en) * 2010-09-24 2015-03-24 Shionogi & Co., Ltd. Substituted polycyclic carbamoyl pyridone derivative prodrug
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2012151361A1 (fr) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Dérivés de carbamoylpyridone
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2613180T3 (es) 2011-09-14 2017-05-23 Mapi Pharma Limited Forma amorfa de la sal sódica dolutegravir
AU2012321762A1 (en) 2011-10-12 2014-04-17 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
WO2013103738A1 (fr) * 2012-01-04 2013-07-11 Gilead Sciences, Inc. Dérivés d'acide naphtalène acétique contre l'infection par le vih
CN105121418A (zh) 2012-04-20 2015-12-02 吉利德科学公司 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
WO2014008636A1 (fr) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Composés macrocycliques en tant qu'inhibiteurs de l'intégrase du vih
US20150166520A1 (en) 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
EP2877469A4 (fr) 2012-07-25 2016-04-06 Merck Sharp & Dohme Dérivés de naphthyridinedione substitués en tant qu'inhibiteurs de l'intégrase du vih
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
SG11201503807TA (en) 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
WO2014099586A1 (fr) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Dérivés 4-pyridinonetriazines en tant qu'inhibiteurs de l'intégrase du vih
SI2822954T1 (sl) * 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
WO2014100077A1 (fr) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Formulations de rétention gastrique
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2940019B1 (fr) 2012-12-27 2018-03-28 Japan Tobacco Inc. DÉRIVÉ SUBSTITUÉ DE SPIROPYRIDO[1,2-a]PYRAZINE ET SON UTILISATION MÉDICALE EN TANT QU'INHIBITEUR D'INTÉGRASE DU VIH
WO2014172188A2 (fr) * 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase
EP3008044B1 (fr) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2015039348A1 (fr) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih
AU2014324829B2 (en) 2013-09-27 2017-09-07 Merck Sharp & Dohme Corp. Substituted Quinolizine Derivatives useful as HIV integrase inhibitors
WO2015089847A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016161382A1 (fr) * 2015-04-02 2016-10-06 Gilead Sciences, Inc. Composés carbamoylpyridones polycycliques et leur utilisation pharmaceutique

Also Published As

Publication number Publication date
AU2015369817A1 (en) 2017-06-22
UY36465A (es) 2016-07-29
ES2732482T3 (es) 2019-11-22
AU2015369817B2 (en) 2018-10-25
EP3237416A1 (fr) 2017-11-01
KR20210042185A (ko) 2021-04-16
KR20190052172A (ko) 2019-05-15
US9522912B2 (en) 2016-12-20
AU2019200422A1 (en) 2019-02-07
EA201791019A1 (ru) 2017-12-29
NZ732391A (en) 2018-12-21
CA2969244C (fr) 2020-05-05
AU2020286299A1 (en) 2021-01-21
PT3237416T (pt) 2019-07-23
CA2969244A1 (fr) 2016-06-30
TW202106688A (zh) 2021-02-16
JP2020073560A (ja) 2020-05-14
MX2017007814A (es) 2017-09-18
TWI695003B (zh) 2020-06-01
US20170119764A1 (en) 2017-05-04
KR102020004B1 (ko) 2019-09-06
US9795602B2 (en) 2017-10-24
TWI738321B (zh) 2021-09-01
KR101978167B1 (ko) 2019-05-14
EP3388431A1 (fr) 2018-10-17
US20160176870A1 (en) 2016-06-23
KR20170097168A (ko) 2017-08-25
KR102240584B1 (ko) 2021-04-15
AR103251A1 (es) 2017-04-26
EP3237416B1 (fr) 2019-05-01
BR102015032109A2 (pt) 2016-07-05
US20210015816A1 (en) 2021-01-21
AU2019200422B2 (en) 2020-09-10
AU2020286299B2 (en) 2022-07-14
JP2018172437A (ja) 2018-11-08
US10646486B2 (en) 2020-05-12
SG11201704421QA (en) 2017-07-28
JP6393835B2 (ja) 2018-09-19
IL252532A0 (en) 2017-07-31
TR201909152T4 (tr) 2019-07-22
KR20190104458A (ko) 2019-09-09
CN107108643A (zh) 2017-08-29
SI3237416T1 (sl) 2019-06-28
JP6934846B2 (ja) 2021-09-15
WO2016106237A1 (fr) 2016-06-30
HK1244000B (en) 2020-05-22
TW201636347A (zh) 2016-10-16
CN111454273A (zh) 2020-07-28
US20180110776A1 (en) 2018-04-26
JP2017538713A (ja) 2017-12-28
PL3237416T3 (pl) 2019-09-30
CN107108643B (zh) 2020-06-05

Similar Documents

Publication Publication Date Title
MA45613A (fr) Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA47440A (fr) Sulfonylurées, composés apparentés, et leur utilisation
IL258931A (en) Therapeutic compounds and methods
EP3493799A4 (fr) Composition pharmaceutique decannabis
MA45709A (fr) Composés diazahétérobicycliques substitués et leur utilisation
MA43364A (fr) Composés d'alcènes tétrasubstitués et leur utilisation
EP3411035A4 (fr) Composés aminothiazole et leur utilisation
PT3341056T (pt) Dispositivos de seringa
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
PL3134152T3 (pl) Układ bezpiecznej strzykawki
EP3493798A4 (fr) Composition pharmaceutique decannabis
EP3454899C0 (fr) Composition pharmaceutique
DK3310414T3 (da) Lægemiddeladministrationsanordning
HUE045234T2 (hu) Gyógyszeradagolás tanulása
MA45113A (fr) Composés mic-1 et leur utilisation
EP3424940A4 (fr) Médicament radiomarqué
EP3351533A4 (fr) Dérivé biaryle et médicament le contenant
EP2953938A4 (fr) Composés de benzopyrane fonctionnalisés et leur utilisation
EP3344613A4 (fr) Composés hétéroaryle et leur utilisation comme médicaments thérapeutiques
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
EP3246047C0 (fr) Médicament d'association
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
HUE048503T2 (hu) Dihidropirimidin-2-on vegyületek és gyógyszerészeti alkalmazásai
EP3383371A4 (fr) Formulation pharmaceutique